​

Neurogene (NGNE) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

NGNE Stock Forecast

Neurogene (NGNE) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $69.00, with a high of $69.00 and a low of $69.00. This represents a 164.47% increase from the last price of $26.09.

$20 $30 $40 $50 $60 $70 High: $69 Avg: $69 Low: $69 Last Closed Price: $26.09

NGNE Stock Rating

Neurogene stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (83.33%), 1 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 1 5 0 Strong Sell Sell Hold Buy Strong Buy

NGNE Price Target Upside V Benchmarks

TypeNameUpside
StockNeurogene164.47%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts112
Avg Price Target$69.00$69.00$57.00
Last Closing Price$26.09$26.09$26.09
Upside/Downside164.47%164.47%118.47%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26-8---8
Mar, 26-8---8
Feb, 26-7---7
Jan, 26-6---6
Dec, 25-6---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 28, 2026Guggenheim$69.00$27.05155.08%164.47%
Oct 02, 2025H.C. Wainwright$45.00$20.61118.34%72.48%
Apr 14, 2025Keith TapperBMO Capital$16.00$10.8946.92%-38.67%
Mar 25, 2025Joel BeattyRobert W. Baird$38.00$14.20167.61%45.65%
Mar 25, 2025Mitchell KapoorH.C. Wainwright$50.00$14.20252.11%91.64%
Nov 20, 2024Paul MatteisStifel Nicolaus$46.00$15.33200.07%76.31%
Nov 19, 2024Keith TapperBMO Capital$45.00$35.5926.44%72.48%
Nov 12, 2024Keith TapperBMO Capital$60.00$64.48-6.95%129.97%
Nov 12, 2024Paul MatteisStifel Nicolaus$60.00$64.48-6.95%129.97%
Aug 12, 2024Mitchell KapoorH.C. Wainwright$49.00$35.5937.68%87.81%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 28, 2026GuggenheimBuyinitialise
Oct 31, 2025H.C. WainwrightBuyBuyhold
Oct 02, 2025H.C. WainwrightBuyBuyhold
Jun 17, 2025Craig-HallumBuyinitialise
Jun 12, 2025BMO CapitalOutperformOutperformhold
Apr 14, 2025BMO CapitalOutperformOutperformhold
Mar 25, 2025H.C. WainwrightBuyBuyhold
Nov 19, 2024BMO CapitalOutperformOutperformhold
Oct 16, 2024BMO CapitalOutperformOutperformhold
Aug 14, 2024BMO CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.83$-4.28$-4.24---
Avg Forecast$-5.58$-4.26$-4.22$-5.01$-4.54$-4.61
High Forecast$-4.71$-3.68$-3.30$-4.42$-4.50$-4.61
Low Forecast$-6.44$-4.51$-4.64$-5.63$-4.58$-4.61
Surprise %-49.28%0.47%0.47%---

Revenue Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$925.00K----
Avg Forecast-$905.00K-$462.50K-$33.00M
High Forecast-$924.89K-$462.50K-$33.00M
Low Forecast-$895.05K-$462.50K-$33.00M
Surprise %-2.21%----

Net Income Forecast

$-95M $-83M $-71M $-59M $-47M $-35M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-36.32M$-75.14M$-90.35M---
Avg Forecast$-71.51M$-52.50M$-50.92M$-64.41M$-58.25M$-59.18M
High Forecast$-60.42M$-47.19M$-42.30M$-56.67M$-57.72M$-59.18M
Low Forecast$-82.60M$-57.81M$-59.53M$-72.16M$-58.78M$-59.18M
Surprise %-49.22%43.13%77.45%---

NGNE Forecast FAQ

Is Neurogene stock a buy?

Neurogene stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Neurogene is a favorable investment for most analysts.

What is Neurogene's price target?

Neurogene's price target, set by 6 Wall Street analysts, averages $69 over the next 12 months. The price target range spans from $69 at the low end to $69 at the high end, suggesting a potential 164.47% change from the previous closing price of $26.09.

How does Neurogene stock forecast compare to its benchmarks?

Neurogene's stock forecast shows a 164.47% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Neurogene over the past three months?

  • April 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Neurogene’s EPS forecast?

Neurogene's average annual EPS forecast for its fiscal year ending in December 2026 is $-5.01, marking a 18.16% increase from the reported $-4.24 in 2025. Estimates for the following years are $-4.54 in 2027, and $-4.61 in 2028.

What is Neurogene’s revenue forecast?

Neurogene's average annual revenue forecast for its fiscal year ending in December 2026 is $462.5K, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $0, and $33M for 2028.

What is Neurogene’s net income forecast?

Neurogene's net income forecast for the fiscal year ending in December 2026 stands at $-64.414M, representing a -28.71% decrease from the reported $-90.351M in 2025. Projections indicate $-58.249M in 2027, and $-59.181M in 2028.